BiotechTube

RDD to Palynziq

ApprovedRecruiting
0 views this week 0 watching⚡ Active💊Featured in Rare Disease Pipeline Watch
Interest: 47/100
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Phenylketonuria

Conditions

Phenylketonuria, PKU

Trial Timeline

Jan 1, 2025 → Nov 1, 2025

NCT ID
NCT06780332

About RDD to Palynziq

RDD to Palynziq is a approved stage product being developed by BioMarin Pharmaceutical for Phenylketonuria. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06780332. Target conditions include Phenylketonuria, PKU.

What happened to similar drugs?

6 of 20 similar drugs in Phenylketonuria were approved

Approved (6) Terminated (1) Active (13)
❌SYNB1934v1 + PlaceboSynlogicPhase 3
🔄Kuvan®MerckPhase 3
✅Kuvan®MerckApproved
🔄Sapropterin dihydrochloride + PlaceboBioMarin PharmaceuticalPhase 3
🔄BMN165 20mg/day + BMN165 40mg/day + PlaceboBioMarin PharmaceuticalPhase 3
🔄sapropterin dihydrochlorideBioMarin PharmaceuticalPhase 3
✅saproterin dihydrochlorideBioMarin PharmaceuticalApproved

Hype Score Breakdown

Clinical
20
Activity
15
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06780332ApprovedRecruiting

Competing Products

20 competing products in Phenylketonuria

See all competitors
ProductCompanyStageHype Score
SYNB1934v1 + PlaceboSynlogicPhase 3
22
SYNB1618 + PlaceboSynlogicPhase 1/2
22
SYNB1618 + SYNB1934SynlogicPhase 2
25
Kuvan®MerckPhase 3
40
Kuvan®MerckApproved
43
SAR444836SanofiPhase 1/2
36
KuvanBioMarin PharmaceuticalPre-clinical
15
rAvPAL-PEGBioMarin PharmaceuticalPhase 2
32
rAvPAL-PEGBioMarin PharmaceuticalPhase 2
32
Sapropterin (Kuvan)BioMarin PharmaceuticalPre-clinical
23
BMN 165 (rAvPAL-PEG)BioMarin PharmaceuticalPhase 2
32
BMN 307BioMarin PharmaceuticalPhase 1/2
33
SapropterinBioMarin PharmaceuticalPre-clinical
23
Sapropterin dihydrochloride + PlaceboBioMarin PharmaceuticalPhase 3
37
BMN165 20mg/day + BMN165 40mg/day + PlaceboBioMarin PharmaceuticalPhase 3
37
sapropterin dihydrochlorideBioMarin PharmaceuticalPhase 3
37
saproterin dihydrochlorideBioMarin PharmaceuticalApproved
40
sapropterin dihydrochloride + Moxifloxacin + Moxifloxacin placeboBioMarin PharmaceuticalPhase 1
26
PegvaliaseBioMarin PharmaceuticalPre-clinical
30
PegvaliaseBioMarin PharmaceuticalPre-clinical
23